Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

    ... research study is to compare how 2 different drugs, decitabine and azacitidine , when given on a shorter than standard ... Azacitidine Decitabine Phase:  ...

    Clinical Trial last updated 04/21/2018 - 5:38pm.

  2. A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients with Myelodysplastic Syndrome (MDS)

    ... second generation compounds such as SGI-110, oral decitabine or oral azacitidine and will also include combinations with ...

    Clinical Trial last updated 04/21/2018 - 5:25pm.

  3. Selinexor (KPT-330) in Older Patients With Relapsed/Refractory AML (SOPRA)

    ... (i) BSC alone, (ii) BSC plus either azacytidine or decitabine or (iii) BSC plus low-dose Ara-C. Overall survival is the ... Azacitidine Decitabine Selinexor (KPT-330) ...

    Clinical Trial last updated 04/17/2018 - 1:51pm.

  4. Treatments

    ... U.S. to treat MDS. Azacitidine (Vidaza®) and decitabine (Dacogen®) are approved to treat both low- and high-risk ...

    Topic section last updated 04/06/2018 - 12:30pm.

  5. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

    ... Decitabine has been explored as a reduced-intensity therapy for older or ... (AML). To better understand the risk of infections during decitabine treatment, we retrospectively examined the culture results from each ...

    Research Article last updated 11/08/2017 - 9:26am.

  6. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the ...

    Research Article last updated 10/23/2017 - 11:00am.

  7. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the ...

    Research Article last updated 10/02/2017 - 10:03am.

  8. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... the impact of DMT-initiation ( azacitidine , decitabine , or lenalidomide ) timing (≤ 3 vs.>3months from start ...

    Research Article last updated 09/13/2017 - 8:58am.

  9. Making Progress for Myelodysplastic Syndromes

    ... medications like Vidaza ( azacitidine ), Dacogen ( decitabine ), Revlimid ( lenalidomide ). We consider transplant as a ...

    Article last updated 07/26/2017 - 10:25am.

  10. Promising news for older AML patients

    ... untreated AML, the combination of venetoclax with either decitabine or azacitidine was associated with a 69% overall ... in Baltimore. “Venetoclax, when combined with decitabine or azacitidine, has a tolerable safety profile in treatment-naive ...

    Article last updated 07/19/2017 - 11:19am.